Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 12/20 | 0.68 |
| ▸ | LOX | P28300 | 1/20 | 0.59 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.59 |
| ▸ | LOXL4 | Q96JB6 | 1/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | AGER | Q15109 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26840374 | 0.88 | CES2 (0.65) | CES2LOXLOXL3LOXL4LOXL2 | |
| SCHEMBL26840379 | 0.88 | CES2 (0.65) | CES2LOXLOXL3LOXL4LOXL2 | |
| SCHEMBL13104005 | 0.81 | CES2 (1.00) | CES2LOXLOXL3LOXL4LOXL2 | |
| SCHEMBL4663174 | 0.80 | CES2 (0.67) | CES2LOXLOXL3LOXL4LOXL2 | |
| SCHEMBL6042079 | 0.80 | CES2 (0.67) | CES2LOXLOXL3LOXL4LOXL2 | |
| SCHEMBL25454224 | 0.79 | CES2 (0.65) | CES2LOXLOXL3LOXL4LOXL2 | |
| SCHEMBL5279293 | 0.79 | CES2 (0.65) | CES2LOXLOXL3LOXL4LOXL2 | |
| SCHEMBL22922974 | 0.79 | CES2 (0.68) | CES2LOXLOXL3LOXL4LOXL2 | |
| SCHEMBL19499378 | 0.79 | CES2 (0.89) | CES2LOXLOXL3LOXL4LOXL2 | |
| SCHEMBL6700291 | 0.78 | CES2 (0.63) | CES2LOXLOXL3LOXL4LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE35801-E | PYRAZOLONE DERIVATIVES | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-05-19 | — | — | US | claimed |
| EP-0208874-B1 | PROPHYLACTIC AND THERAPEUTIC AGENT FOR CIRCULATORY DISORDERS | MITSUBISHI KASEI CORPORATION (JP) | 1993-03-24 | — | — | EP | claimed |
| US-4857542-A | INHIBITOR AGAINST LIPID PEROXIDATION | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1989-08-15 | — | — | US | claimed |
| EP-0208874-A1 | Prophylactic and therapeutic agent for circulatory disorders | MITSUBISHI KASEI CORPORATION (JP) | 1987-01-21 | — | — | EP | claimed |
| US-20230364059-A1 | STABLE PHARMACEUTICAL COMPOSITION | JIANGSU SIMCERE PHARMACEUTICAL CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20210128529-A1 | DRUG CONTAINING PYRAZOLONE DERIVATIVE | NOBELPHARMA CO., LTD. (JP) | 2021-05-06 | — | — | US | disclosed |
| CN-112118839-A | Pyrazolone derivative-containing drug | 耐贝医药株式会社 | 2020-12-22 | — | — | CN | disclosed |
| EP-3666270-A1 | DRUG CONTAINING PYRAZOLONE DERIVATIVE | Nobelpharma Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| EP-1793821-B1 | PYRAZOLONE COMPOUNDS FOR TREATING CEREBROVASCULAR DISORDERS | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-10-31 | — | — | EP | disclosed |
| US-10004720-B2 | Agent for preventing and/or treating ophthalmologic diseases | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-06-26 | — | — | US | disclosed |
| EP-3321255-A1 | NOVEL THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) OR DISEASE ATTRIBUTABLE TO ALS | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
| US-20170273949-A1 | AGENT FOR PREVENTING AND/OR TREATING OPHTHALMOLOGIC DISEASES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-09-28 | — | — | US | disclosed |
| EP-1553087-A1 | PREVENTIVE AND/OR THERAPEUTIC DRUGS FOR INFLAMMATORY INTESTINAL DISEASES | Mitsubishi Pharma Corporation (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-20050009896-A1 | Particularly 3-methyl-1-phenyl-2-pyrazolin-5-one; thrombolytic agent, an anticoagulant and/or a platelet aggregation inhibitory agent such as a thromboxane synthetase inhibitor; for treating and/or preventing ischemic diseases which are safe and have few side effects | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040254234-A1 | Medicament for prevention and/or therapy of arterial wall disorder | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1437137-A1 | DRUGS COMPRISING COMBINATION OF ANTITHROMBOTIC AGENT WITH PYRAZOLONE DERIVATIVE | Mitsubishi Pharma Corporation (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-RE35801-E | PYRAZOLONE DERIVATIVES | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-05-19 | — | — | US | disclosed |
| EP-0208874-B1 | PROPHYLACTIC AND THERAPEUTIC AGENT FOR CIRCULATORY DISORDERS | MITSUBISHI KASEI CORPORATION (JP) | 1993-03-24 | — | — | EP | disclosed |
| US-4857542-A | INHIBITOR AGAINST LIPID PEROXIDATION | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1989-08-15 | — | — | US | disclosed |
| EP-0208874-A1 | Prophylactic and therapeutic agent for circulatory disorders | MITSUBISHI KASEI CORPORATION (JP) | 1987-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273949-A1 | AGENT FOR PREVENTING AND/OR TREATING OPHTHALMOLOGIC DISEASES | MITF, EYA3, AQP1 | CES2 4863/4885LOX 969/4885LOXL3 1562/4885 |
| US-20040254234-A1 | Medicament for prevention and/or therapy of arterial wall disorder | ADRB3, TNNI3, AGTR1 | CES2 944/4885LOX 680/4885LOXL3 959/4885 |
| US-20230364059-A1 | STABLE PHARMACEUTICAL COMPOSITION | SYMPK, CYP3A7, CYP3A5 | CES2 1270/4885LOX 4605/4885LOXL3 4716/4885 |
| US-20050009896-A1 | Particularly 3-methyl-1-phenyl-2-pyrazolin-5-one; thrombolytic agent, an anticoagulant and/or a platelet aggregation inhibitory agent such as a thromboxane synthetase inhibitor; for treating and/or preventing ischemic diseases which are safe and have few side effects | PLAT, PTGIS, SERPINC1 | CES2 3502/4885LOX 426/4885LOXL3 1933/4885 |
| US-20210128529-A1 | DRUG CONTAINING PYRAZOLONE DERIVATIVE | CYP11B2, CYP3A5, DPYD | CES2 2886/4885LOX 3182/4885LOXL3 3719/4885 |
| US-10004720-B2 | Agent for preventing and/or treating ophthalmologic diseases | MITF, EYA3, AQP1 | CES2 4863/4885LOX 969/4885LOXL3 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.